CN102408998A - Salt-tolerant marine mangrove endophytic fungi with neurodegenerative disease control activity - Google Patents
Salt-tolerant marine mangrove endophytic fungi with neurodegenerative disease control activity Download PDFInfo
- Publication number
- CN102408998A CN102408998A CN201110177763XA CN201110177763A CN102408998A CN 102408998 A CN102408998 A CN 102408998A CN 201110177763X A CN201110177763X A CN 201110177763XA CN 201110177763 A CN201110177763 A CN 201110177763A CN 102408998 A CN102408998 A CN 102408998A
- Authority
- CN
- China
- Prior art keywords
- mangrove
- endogenetic fungus
- salt tolerance
- ocean
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000002044 Rhizophora apiculata Species 0.000 title claims abstract description 75
- 241000233866 Fungi Species 0.000 title claims abstract description 68
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 30
- 230000000694 effects Effects 0.000 title abstract description 11
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 230000015784 hyperosmotic salinity response Effects 0.000 claims description 49
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- 210000005036 nerve Anatomy 0.000 claims description 29
- 241000894006 Bacteria Species 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 20
- 239000011780 sodium chloride Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960002523 mercuric chloride Drugs 0.000 claims description 3
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 abstract description 13
- 230000002776 aggregation Effects 0.000 abstract description 9
- 238000004220 aggregation Methods 0.000 abstract description 9
- 229930000044 secondary metabolite Natural products 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 3
- 241000588724 Escherichia coli Species 0.000 abstract description 2
- 230000006933 amyloid-beta aggregation Effects 0.000 abstract 4
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000011160 research Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 101800001718 Amyloid-beta protein Proteins 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 7
- 239000012452 mother liquor Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229960002920 sorbitol Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000228143 Penicillium Species 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000000452 restraining effect Effects 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 5
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 4
- 241001480007 Phomopsis Species 0.000 description 4
- 244000037433 Pongamia pinnata Species 0.000 description 4
- 235000004599 Pongamia pinnata Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000007131 anti Alzheimer effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000355188 Phomopsis occulta Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GGRLKHMFMUXIOG-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].CC(=O)OCC[N+](C)(C)C GGRLKHMFMUXIOG-UHFFFAOYSA-M 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010013976 Dyspraxia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 1
- 241000862501 Kandelia candel Species 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000003793 Rhizophora mangle Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001116498 Taxus baccata Species 0.000 description 1
- 241000015728 Taxus canadensis Species 0.000 description 1
- 241001557892 Xylaria sp. Species 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- GWHQHAUAXRMMOT-MBANBULQSA-N rivastigmine tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 GWHQHAUAXRMMOT-MBANBULQSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229930183522 sporothrin Natural products 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229930182970 xyloketal Natural products 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the technical field of microorganisms and discloses salt-tolerant marine mangrove endophytic fungi with neurodegenerative disease control activity. The endophytic fungi are separated from the mangrove barks, and the collection number of the endophytic fungi is CCTCC (China Center for Type Culture Collection) M2011044. The secondary metabolites and extracts of the salt-tolerant marine mangrove endophytic fungi SN3-2 have obvious activity against AD (Alzheimer's disease). The extracts of the endophytic fungi have strong A-beta aggregation inhibiting effect when the E.coli cell model is used for screening and studying the activity against A-beta aggregation, and the extracts of the endophytic fungi have stronger activity against aggregation when the in-vitro A-beta aggregation model is used for testing the activity against A-beta aggregation.
Description
Technical field
The present invention relates to the research of application and the nerve degenerative diseases control activeconstituents of marine microorganism, a kind of specifically have nerve degenerative diseases and prevent and treat active ocean mangrove salt tolerance endogenetic fungus.
Background technology
Nerve degenerative diseases is a kind of frequently-occurring disease and common disease clinically; Comprise A Ercicaimo sick (Alzheimer ' s disease; AD), Parkinson's disease (Parkinson ' s disease; PD), HD (Huntington ' s disease, HD) etc., cardinal symptom comprises the memory of carrying out property and cognition dysfunction, dyspraxia or the like.Along with the aging of human society age structure, the nerve degenerative diseases sickness rate raises day by day, has become the third-largest worldwide health problem that is only second to cardiovascular and cerebrovascular diseases and tumour.
People have carried out big quantity research to the pathogeny of nerve degenerative diseases in recent years, and pathogeny has been proposed some different hypothesis, like entanglement and gathering, the oxidative stress of key protein, biological metal ion stable state is unbalance, mitochondrial function depletion etc.Yet the pathogenic factor of nerve degenerative diseases and mechanism are still very not clear and definite at present.Existing result of study shows; As a big proteinoid false folding sick (molecular conformation is sick); The aggregate and precipitate of the relevant key protein of nerve degenerative diseases has important regulating effect in pathogenic process; Morbidity like AD is promptly directly related with the cytotoxicity that gathering, deposition and the oligomer of A-beta key proteins such as (beta-amyloid) produce; Proteic overexpression of A-beta and gathering, deposition can cause directly that mitochondrial disorders, oxidative stress, nerve synapse transmission interruption, aixs cylinder transportation are interrupted, the impaired multiple AD related pathologies such as break of film integrality changes, and the morbidity of HD is directly related with the gathering of Poly Q etc.Therefore, the aggregate and precipitate of nerve degenerative diseases GAP-associated protein GAP has become research nerve degenerative diseases pathogeny and one of nerve degenerative diseases medicine and the most important target of method.
Though the nerve degenerative diseases GAP-associated protein GAP forms insoluble fibre through the folding crosslinked gathering of β sheet, the death of neurocyte finally appears and causes with block high polymer form.But result of study proves recently, and the soluble proteins oligomer that in forming the insoluble fibre process, produces is only its neurovirulent material of real embodiment.Therefore; Compare with the aggregation inhibitor of research fiber or block high polymer, research has prior theory significance and value for nerve degenerative diseases control activeconstituents to inquire into the aggregation inhibitor of screening study nerve degenerative diseases GAP-associated protein GAP oligomer how.
With nerve degenerative diseases deeply the comparing gradually of mechanism research of curing the disease, nerve degenerative diseases control medicine correlative study and using then obviously lags behind, and does not still have etiotropic specific treatment medicine up to now clinically.Existing medicine has only certain auxiliaring effect to the state of an illness of nerve degenerative diseases; Can delay the deterioration of the state of an illness to a certain extent; But all can not reverse disease; Like anti-AD medicine is example; Existing acetylcholinesterase depressant (IChEIs) is like tacrine, donepezil, huperzine, ENA-713, fuperdin A etc. and be used for clinical uncompetitive nmda receptor antagonist hydrochloric acid memantine (memantine) medicine of etc.ing in recent years certain adjuvant treatment effect is all only arranged, and much also can cause the vagusstoff related reactions under the situation.Therefore; Discovering new, special habitats nerve degenerative diseases control medicine resource and find that therefrom the unique novel active composition of novel structure, effect is very important for the research of nerve degenerative diseases lead drug, is one of core means that solve the nerve degenerative diseases new drug development.
Mangrove forest is a kind of very special ecological zone between marine ecology and land ecology.The influence that receives mangrove forest height salt dutyization, the anoxic of soil, high optical radiation and periodic seawater to soak unique growing environments such as flooding, the very abundant mangrove forest Microbial resources that have characteristic have again become one of unique ocean medicine resource.After separation obtained producing the endogenetic fungus Taxamyces andrenae of novel active from Pacific yew (yewtree) in 1993, the research of mangrove plant endogenetic fungus active substance had caused people's very big interest.At present, both at home and abroad in mangrove endogenetic fungus secondary metabolite isolation identification unique, the novel compounds of a plurality of structures, have antitumor, antiviral, antibiotic isoreactivity.Wherein the sporothrins A of isolation identification and Xylaria sp. meta-bolites Xyloketal A-D have stronger restraining effect to E.C. 3.1.1.7 from Kandelia candel bark endogenetic fungus thalline.This just further proves: mangrove endogenetic fungus and metabolite thereof have great DEVELOPMENT PROSPECT as the resource of nerve degenerative diseases control new drug research.
Summary of the invention
Main purpose of the present invention be to provide a kind of from mangrove yellow water skin rhizome portion bark isolating ocean mangrove salt tolerance endogenetic fungus; It is active that this mangrove endogenetic fungus thalline extract has the nerve degenerative diseases control, and it is active in the E.coli of A-beta protein aggregation cell model, to demonstrate good anti-A-beta protein aggregation.
Ocean of the present invention mangrove salt tolerance endogenetic fungus is identified through Institute of Microorganism, Academia Sinica; Called after: Phomopsis occulta; Hide the little mirror word of Phomopsis (2011) No. 019); It is preserved in Luojiashan, Wuchang, Wuhan City, Hubei Province Wuhan University preservation center on February 23rd, 2011, promptly Chinese typical culture collection center (CCTCC), and deposit number is CCTCCM2011044.The application is to its called after SN3-2.
The solid culture of ocean of the present invention mangrove salt tolerance endogenetic fungus is characterized as:
The PDA solid medium, cultivated 6 days in 25 ℃ of darkrooms, and bacterium colony is a white hair shape, and neat in edge has the Steel Gray point when ripe; Crawl shape growth of mycelia is separated, and gives birth in the spore.
This bacterium has stronger salt tolerance: not containing well-grown on the PDA substratum of NaCl, on the high salinity PDA substratum that contains 1M, 2M, 3M NaCl, all grow fine, explain that this bacterium has very strong salt tolerance; But this bacterium does not have halophilism, because grow fine not containing on the NaCl PDA substratum.This bacterium also has stronger anti-oozing property: it is all very good that ocean of the present invention mangrove salt tolerance endogenetic fungus oozes on the substratum growing way at the PDA solid height that contains 2M, 3M Sorbitol Powder (sorbitol); And to the growing way basically identical of different concns Sorbitol Powder PDA substratum, this this bacterium of explanation has anti-the oozing property of stronger Sorbitol Powder.
Ocean mangrove salt tolerance endogenetic fungus SN3-2 of the present invention well-grown in the fungi basic culture solution: grow fine not containing NaCl and contain respectively in the liquid nutrient medium of 1M, 2M, 3M NaCl; The speed that this bacterium grows in the substratum that contains different N aCl concentration is different, and along with the increase of NaCl concentration, the speed of growth of bacterium continues to reduce, but colonial morphology, mycelia and conidium etc. are consistent.
The base sequence of the 18srDNA of ocean of the present invention mangrove salt tolerance endogenetic fungus is shown in SEQ ID NO:1.
The method of separating marine mangrove salt tolerance endogenetic fungus from the bark of mangrove rhizome portion:
1, the mangrove branch surface that collects is cleaned, brought into sterilisable chamber.Branch is surperficial with flame sterilization 10s~15s.With aseptic cutter it is cut into the segment of 3cm~4cm, 75% alcohol disinfecting 10min, 0.1% mercuric chloride soaks 3min.With sterilized water washing 5 times.Other establishes control group (with the sterilized water of last washing as contrast).The branch segment is inoculated in respectively on the PDA solid medium plate of the NaCl that contains concentration 1M and 3M (every kind of material 3 wares, 3 sections branches of every ware), is positioned in 25 ℃ of thermostat containers and cultivates;
2, wait to grow bacterium colony after, choose the tip of mycelia by the aseptic technique program, be inoculated on the PDA solid medium plate, carry out the separation and purification of bacterial classification, obtain the mangrove endogenetic fungus.
3, purebred bacterial strain being inserted the Sha Shi test tube slant preserves.Switching in per 3 months~4 months once.
The method of isolation of genomic DNA from the mangrove salt tolerance endogenetic fungus of ocean according to the invention:
It is active that ocean of the present invention mangrove salt tolerance endogenetic fungus SN3-2 secondary metabolite and thalline extract have significant nerve degenerative diseases control.Carrying out the nerve degenerative diseases key protein with external A-beta 42 Aggregation Model, Poly Q model etc. assemble to suppress screening active ingredients and discovers; This bacterium thalline extract has very strong A-beta, Poly Q assembles restraining effect, and it is active to demonstrate stronger nerve degenerative diseases control.
Anti-A-beta in the mangrove salt tolerance endogenetic fungus SN3-2 thalline extract of ocean of the present invention assembles effective constituent and has better water solubility; All more stable under the aqueous solution, organic solution, neutrallty condition, weak acid alkali condition, handle 120min successor at 70 ℃ and so keep the activity more than 95%.
It is active that ocean mangrove salt tolerance endogenetic fungus SN3-2 of the present invention has stronger anti-AD; Contain in its secondary metabolite is the anti-gathering type anti-AD active substance of target spot in a large number with the A-beta gathering; Possess the great potential of therefrom finding novel anti AD lead drug, will provide support for the research of novel anti AD medicine.The present invention has very important meaning and value to the research of AD specific medicament and the deep development of China's South Sea mangrove resource.
Description of drawings
Figure 1A and Figure 1B are respectively colonial morphology figure and the micro-structure diagram of ocean mangrove salt tolerance endogenetic fungus SN3-2 according to the invention, and micro-magnification is 1000.
Fig. 2 is the genomic dna nucleic acid agarose electrophoresis figure for ocean mangrove salt tolerance endogenetic fungus SN3-2 according to the invention and part correlation ocean mangrove salt tolerance endogenetic fungus; M: molecular weight is the nucleic acid Marker of 15000bp; 5 is the SN3-2 genomic dna, and 1-4 and 6 is respectively the genomic dna of part correlation ocean mangrove salt tolerance endogenetic fungus.
Fig. 3 is the external A-beta42 Aggregation Model of the thalline extract result of study of ocean mangrove salt tolerance endogenetic fungus SN3-2 according to the invention.
Fig. 4 is the external Poly Q of the thalline extract Aggregation Model result of study of ocean mangrove salt tolerance endogenetic fungus SN3-2 according to the invention.
Embodiment
The whole thinking of the present invention comprise following some: separating marine mangrove salt tolerance endogenetic fungus from the mangrove branch; Isolation of genomic DNA from the mangrove salt tolerance endogenetic fungus of ocean; Clone 18SrDNA sequence from the mangrove salt tolerance endogenetic fungus genome of ocean; The ocean mangrove salt tolerance endogenetic fungus that separation is obtained carries out salt tolerance, halophilism and anti-oozing property and analyzes; Extract ocean mangrove salt tolerance endogenetic fungus secondary metabolite, detect its anti-A-beta aggregation activity; Above each point is all independent embodiment, below will combine specific embodiment to explain further details.
The Pongamia glabra that marine site, Shenzhen mangrove Pongamia glabra is gathered according to following conditional filtering and cultivation, promptly can obtain the described ocean of this patent mangrove salt tolerance endogenetic fungus SN3-2 near root water surface top bark sample in the laboratory.
(1) substratum and preparation:
(1) PDA solid medium: yam 200g cleans peeling, adds water 800ml, boils 30min, six layers of filtered through gauze; Filtrating adds agar 15g, and adding glucose 20g, penicillium mould final concentration are that 80u/ml, Streptomycin sulphate final concentration are 36u/ml.0.1MPa, 121 ℃ of sterilization 30min, glucose, penicillium mould, Streptomycin sulphate are sterilized through filtering mode.
Penicillium mould specification: 1600u/mg, the 5g dress.Compound method: take by weighing 500mg and dissolve in the 10ml water, be mixed with the penicillium mould mother liquor, filter the back and preserve.Add 1ml penicillium mould mother liquor in every liter of substratum during preparing culture medium.The penicillium mould final concentration is 80u/ml.
Sulfuric acid strepto-specification is 720u/mg, the 10g dress.Compound method: take by weighing 500mg and dissolve in the 10ml water, be mixed with the Vetstrep mother liquor, filter the back and preserve.Add 1ml Vetstrep mother liquor in every liter of substratum during preparing culture medium.The Vetstrep final concentration is 36u/ml.
(2) the PDA solid contains salt culture medium: in the PDA solid medium, add NaCl, the PDA solid that obtains containing NaCl concentration and be 1M and 3M contains salt culture medium.
(3) PDA solid height oozes substratum: in the PDA solid medium, add D-sorbitol, obtaining containing sorbitol concentration is 2M, 3M, and the PDA solid height of 4M oozes substratum.
(4) fungi basic culture solution: peptone (peptone) 0.3%, ammonium sulfate 0.2%, yeast extract paste 0.05%; Potassium primary phosphate 0.4%, calcium chloride 0.03%, MAGNESIUM SULPHATE HEPTAHYDRATE 99.5 0.03%; Glucose 10g/L adds the different NaCl that measure respectively, makes its NaCl content be respectively 0-3M.0.1MPa, 121 ℃ of sterilization 30min.
(5) MS substratum:
Macroelement mother liquor (20 * 1L): 33g NH
4NO
3, 38g KNO
3, 8.8g CaCl
22H
2O, 7.4g MgSO
47H
2O, 3.4g KH
2PO
4
Trace element mother liquor (200 * 1L): 4.46g MnSO
4H
2O, 1.72g ZnSO
47H
2O, 0.005g CoCl
26H
2O, 0.005g CuSO
45H
2O, 1.24g H
3BO
3, 0.05g Na
2MO
42H
2O, 0.166g KI.
Mother liquid of iron salt (200 *, 1L): 5.74g FeSO47H2O, 7.46g EDTA.
Organism mother liquor (200 * 1L): 0.2g nicotinic acid, 0.2g pyridoxine hydrochloride (VB
6), 0.04g vitamin, 40g inositol, 0.8g glycocoll.
MS root media (1L): 50ml macroelement (20 *), 5ml trace element (200 *), 5ml organic element (200 *), 5ml molysite (200 *), 30g sucrose, NAA (0.2mg/L), the 10g agar powder, pH 6.0, autoclaving.
(2) concrete separation method
The collection Pongamia glabra, is cleaned the material surface that collects as parting material near root water surface top bark from the mangrove Pongamia glabra of marine site, Shenzhen, brings sterilisable chamber into.Branch is surperficial with flame sterilization 10s~15s.With aseptic cutter it is cut into the segment of 3cm~4cm, 75% alcohol disinfecting 10min, 0.1% mercuric chloride soaks 3min.With sterilized water washing 5 times.Other establishes control group (with the sterilized water of last washing as contrast).The branch segment is inoculated in respectively on the PDA solid medium plate of the NaCl that contains concentration 1M and 3M (every kind of material 3 wares, 3 sections branches of every ware), is positioned in 25 ℃ of thermostat containers and cultivates; After waiting to grow bacterium colony, choose the tip of mycelia, be inoculated on the PDA solid medium plate by the aseptic technique program; Carry out the separation and purification of bacterial classification, obtain ocean mangrove salt tolerance endogenetic fungus, called after Phomopsis occulta; Hide Phomopsis, the application abbreviates SN3-2 as.
Purebred bacterial strain is inserted the Sha Shi test tube slant to be preserved.Switching in per 3 months~4 months once.
SN3-2 is Phomopsis (Phomopsis), and cultivated 7 days in 25 ℃ of darkrooms, observes its morphological specificity and microscopic features, describes to see table 1 and Figure 1A, Figure 1B for details.
The cultural characteristic of table 1 ocean according to the invention mangrove salt tolerance endogenetic fungus SN3-2
The ocean mangrove salt tolerant endogenetic fungus bacterial classification that is separated to is inoculated into respectively to contain NaCl concentration be 1M, 2M, the high salt culture medium of PDA solid of 3M is cultivated in 25 ℃ of darkrooms, and its upgrowth situation of record is seen table 2 after 7 days.
Table 2 ocean mangrove salt tolerance endogenetic fungus is to the tolerance of salinity qualification result of NaCl
Annotate: one "+" expression bacterium colony covers with 1/4 flat board, and "-" expression bacterium colony is not grown.
Ocean mangrove salt tolerant endogenetic fungus bacterial classification behind the purifying is seeded in respectively contains on the salt-free PDA solid medium flat board of 1M NaCl/, cultivate in 25 ℃ of darkrooms, the record growing state, whether detect has halophilic bacterium.The result sees table 3, can know that SN3-2 is non-halophilic bacterium.
Table 3 ocean mangrove salt tolerant endogenetic fungus halophilism detected result
Annotate: "+" expression bacterium colony has growth, and "-" expression bacterium colony is not grown.
The ocean mangrove salt tolerant endogenetic fungus bacterial classification that is separated to is inoculated into respectively to contain Sorbitol concentration be 2M, 3M, the PDA solid height of 4M oozes substratum, cultivates in 25 ℃ of darkrooms, writes down its upgrowth situation, measures its anti-degree of oozing, and the result sees table 4.
Anti-the oozing property qualification result of table 4 ocean mangrove salt tolerance endogenetic fungus
Annotate: "+" expression bacterium colony covers with 1/4 flat board, and "-" expression bacterium colony is not grown.
Isolation of genomic DNA agarose gel electrophoresis result sees Fig. 2 in the mangrove salt tolerance endogenetic fungus of ocean.
From the mangrove salt tolerance endogenetic fungus genomic dna of ocean, separate 18SrDNA, its base sequence is shown in SEQ ID NO:1.
(1) extraction of ocean according to the invention mangrove salt tolerance endogenetic fungus SN3-2 secondary metabolite preparation:
(1) ocean mangrove salt tolerance endogenetic fungus SN3-2 according to the invention at first is seeded to the fungi basic culture solution by the PDA solid medium that contains different concns NaCl; Be transferred to respectively after 2 days and contain 0,1,2, coerce cultivation among each 50L of fungi basic culture solution of 3M NaCl, 25 ℃ leave standstill and cultivated 40 days;
(2) different concns NaCl fungi basic culture solution filters respectively, and the fermented liquid merging is concentrated into 1L, uses the equal-volume ethyl acetate extraction 3 times, and extraction liquid merges, and low temperature (45 ℃) decompression is divided exactly solvent and got SN3-2 fermented liquid extract;
(3) thalline difference low-temperature vacuum drying,, dipping ultrasonic with 3L methyl alcohol extracts 3 times, and extracting solution merges, and low temperature (45 ℃) decompression is divided exactly solvent and is got SN3-2 bacterium thalline extract;
(4) according to the characteristic of different sorts composition, adopt methods such as TLC, SGCC, HPLC, HPCE, FS to crude extract separate repeatedly, purifying, and finally obtain the meta-bolites monomer.
(2) the external A-beta42 Aggregation Model of ocean mangrove salt tolerance endogenetic fungus secondary metabolite according to the invention research:
ThT analyzes and uses synthetic A β 42 polypeptide, and 37 ℃ left standstill 2 hours, added final concentration 100 each sample of μ g/mL, and with the fluorescence intensity of fluorescence microplate reader test reaction system, excitation wavelength is 444nm, and emission wavelength is 485nm.With the negative contrast of DMSO, the positive contrast of EGCG can judge that according to the difference of system fluorescence intensity component suppresses active to the A-beta accumulative.Experimental result is referring to Fig. 3.The experimental result explanation: a plurality of sample relative intensity of fluorescence are lower, A-beta42 assembled have remarkable restraining effect, and the sample segment restraining effect is better than positive control sample EGCG or approaching with it.
(3) the external Poly Q of ocean mangrove salt tolerance endogenetic fungus secondary metabolite according to the invention Aggregation Model research:
ThT analyzes and uses purifying Poly Q albumen, and 37 ℃ left standstill 2 hours, added final concentration 100 each sample of μ g/mL, and with the fluorescence intensity of fluorescence microplate reader test reaction system, excitation wavelength is 444nm, and emission wavelength is 485nm.With the negative contrast of DMSO, the positive contrast of EGCG can judge that according to the difference of system fluorescence intensity component suppresses active to Poly Q accumulative.Experimental result is referring to Fig. 4.The experimental result explanation: a plurality of sample relative intensity of fluorescence are lower, Poly Q assembled have remarkable restraining effect, and sample segment restraining effect and positive control sample EGCG are approaching.
Claims (5)
1. one kind has nerve degenerative diseases and prevents and treats active ocean mangrove salt tolerance endogenetic fungus, and its deposit number is CCTCC M2011044.
2. according to claim 1 a kind ofly have nerve degenerative diseases and prevent and treat active ocean mangrove salt tolerance endogenetic fungus, and it is characterized in that: the base sequence of its 18srDNA is shown in SEQ ID NO:1.
3. the method for separating marine mangrove salt tolerance endogenetic fungus from the mangrove bark may further comprise the steps:
1) gets the mangrove bark, clean, bring the sterilisable chamber sterilization into;
2) the mangrove bark of will sterilizing is inoculated in respectively on the PDA solid medium plate of the NaCl that contains concentration 1M and 3M, is positioned in 25 ℃ of thermostat containers and cultivates;
3) wait to grow bacterium colony after, choose the tip of mycelia by the aseptic technique program, be inoculated on the PDA solid medium plate, carry out the separation and purification of bacterial classification, obtain ocean mangrove salt tolerance endogenetic fungus.
4. according to claim 3 from the mangrove bark method of separating marine mangrove salt tolerance endogenetic fungus, it is characterized in that: said mangrove bark is the bark near root water surface top.
According to claim 3 or 4 described from the mangrove bark method of separating marine mangrove salt tolerance endogenetic fungus; It is characterized in that: said mangrove bark is after using sterilization behind the surface sterilization; Aseptic cutter is cut into the segment of 3cm~4cm with it, soaks sterilization with alcohol and mercuric chloride again.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110177763 CN102408998B (en) | 2011-06-28 | 2011-06-28 | Salt-tolerant marine mangrove endophytic fungi with neurodegenerative disease control activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110177763 CN102408998B (en) | 2011-06-28 | 2011-06-28 | Salt-tolerant marine mangrove endophytic fungi with neurodegenerative disease control activity |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102408998A true CN102408998A (en) | 2012-04-11 |
CN102408998B CN102408998B (en) | 2013-06-05 |
Family
ID=45911352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110177763 Expired - Fee Related CN102408998B (en) | 2011-06-28 | 2011-06-28 | Salt-tolerant marine mangrove endophytic fungi with neurodegenerative disease control activity |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102408998B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9114130B2 (en) | 2013-05-06 | 2015-08-25 | University Of South Florida | Compounds and related methods for treatment of neurodegenerative diseases |
CN111032061A (en) * | 2017-06-14 | 2020-04-17 | 4D制药研究有限公司 | Compositions comprising bacterial strains |
-
2011
- 2011-06-28 CN CN 201110177763 patent/CN102408998B/en not_active Expired - Fee Related
Non-Patent Citations (6)
Title |
---|
《2011年全国药物化学学术会议--药物的源头创新论文摘要集》 20111119 张昉等 海洋红树耐盐微生物SN5-1及其抗AD活性研究 第316页 1-5 , * |
《2011年全国药物化学学术会议--药物的源头创新论文摘要集》 20111119 张燎等 红树耐盐内生真菌SN3-2及其对Abeta42寡聚体聚集生成抑制活性研究 第317页 1-5 , * |
孟旭鹏等: "海洋细菌Roseobacter sp.发酵液中化学成分的研究", 《中国海洋药物杂志》 * |
张昉等: "海洋红树耐盐微生物SN5-1及其抗AD活性研究", 《2011年全国药物化学学术会议——药物的源头创新论文摘要集》 * |
张燎等: "红树耐盐内生真菌SN3-2及其对Aβ42寡聚体聚集生成抑制活性研究", 《2011年全国药物化学学术会议——药物的源头创新论文摘要集》 * |
王芳芳等: "海洋红树植物桐花树内生菌GT20021545发酵液的化学成分研究", 《中国海洋药物杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9114130B2 (en) | 2013-05-06 | 2015-08-25 | University Of South Florida | Compounds and related methods for treatment of neurodegenerative diseases |
CN111032061A (en) * | 2017-06-14 | 2020-04-17 | 4D制药研究有限公司 | Compositions comprising bacterial strains |
US11660319B2 (en) | 2017-06-14 | 2023-05-30 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11779613B2 (en) | 2017-06-14 | 2023-10-10 | Cj Bioscience, Inc. | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102408998B (en) | 2013-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103952362B (en) | One strain is to the oranges and tangerines endogeny rayungus of various plants pathogenic bacteria tool bacteriostatic activity | |
CN102037856B (en) | Simple cordyceps militaris strain rejuvenation method | |
CN108587981B (en) | Streptomyces amyrosarensis and application thereof | |
CN106544278A (en) | A kind of pathogenic fungi for Blatta seu periplaneta Biological control | |
CN103563655A (en) | Technique for cultivating living pupation cordyceps | |
CN102154407A (en) | Corayceps militaris polysaccharide two-stage fermentation synthesis process | |
CN106479943A (en) | The Java Isaria BE01 of one plant height effect preventing and treating fall webworms and its application | |
CN101942393A (en) | Huperzia serrata endophytic fungus shiraia sp. strain for producing huperzine A | |
CN103667070A (en) | Plant endophytic fungi of huperzia serrata and application thereof in preparing huperzine A | |
CN104195064B (en) | The Oryza sativa L. endogeny rayungus of the one external efficient antagonism Pyricularia oryzae of strain | |
Vanucci et al. | Cell growth and toxins' content of Ostreopsis cf. ovata in presence and absence of associated bacteria | |
CN108004271B (en) | Streptomyces with algae-lysing activity and application thereof | |
CN102408998B (en) | Salt-tolerant marine mangrove endophytic fungi with neurodegenerative disease control activity | |
CN101487022B (en) | Preparation of fermentation liquor for inhibiting liver cancer cell growth | |
CN109182151A (en) | The separating screening method of gingko endogenous fungus | |
CN101375689B (en) | Black oyster mushroom extract as well as preparation method and application thereof | |
CN102168039B (en) | Method for screening extracellular algae-killing protein marine bacteria | |
CN104686587B (en) | A kind of natural algae-inhibiting agent of algae and its preparation method and application | |
CN103704022A (en) | Method for cultivating artificial cordyceps sinensis with five-instar silkworms as carrier | |
CN102168108B (en) | Cordyceps cardinalis, method for preparing oosporin by using same and application of Cordyceps cardinalis | |
CN103103134A (en) | Huperzia serrata endophytic fungi and its use in production of huperzine a | |
CN113481108B (en) | Nutritional matrix for stimulating growth of nematode-trapping fungi on trunk, and preparation method and application method thereof | |
CN109077068A (en) | A kind of application of fungi rod method in prevention and control exotic invasive weed Yellow calla | |
Dhanam Jayam et al. | Screening and characterization of L-asparaginase Producing Streptomyces isolated from soil samples of Periyar Lake, Kumily | |
CN112143669B (en) | Cyanobacteria algae and culture method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130605 |